RE:RE:Just how much market share is TOS taking from ASP (JnJ)?Getinge had, by any measure, a bad quarter. Myers did, however, mention a couple of times that the Infection Control division was a positive in a quarter with otherwize negative top line growth. And, of course, he did not, as he did in the last cc, specifically mention TSO3 's VP4 as a 'star' product. He did, however, mention a couple of times, that Getinge's relatiionship with FDA is very strained, related to awaiting FDA decisions related to the Consent Decree about resolving compiance and standards issues from the Atrium and other medical manufacturing facilities. All in all, I would say the Getinge CEO did his best to be as opaque as possible while putting a positive spin on a disappointing quarter, blaming internal reorganization, again, for many of the shortfalls.
But, it is again apparent why Getinge is very happy to have TSO3 continue to deal directly with FDA quite independently: the FDA - Getinge relationship, while they are talking to each other, remains a very, very sour one. And, given Getinge's most recent disasterous acquisitions, (Atrium, for example), is it any wonder they are letting TSO3 remain independent until the FDA process is more complete?
But, once TSO3 has made more progress with FDA, and as market penetration and industry superiority become more apparent, and it becomes even more obvious how extremely undervalued this company is, Getinge will certainly be only one of many bidders in the running to acquire this little gem. IMHO, of course. :) WKH